RaySearch Laboratories AB

  • Market Cap: Small Cap
  • Industry: Software Products
  • ISIN: SE0000135485
SEK
225.00
213.85 (1917.94%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

62.76 k

Shareholding (Jun 2021)

FII

0.00%

Held by 1 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With ROE of 22.73%, it has a expensive valuation with a 9.49 Price to Book Value

  • The stock is trading at a discount compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 4.17%, its profits have risen by 27.6% ; the PEG ratio of the company is 1.5
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Software Products

stock-summary
Market cap

SEK 6,499 Million (Small Cap)

stock-summary
P/E

42.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

1.23%

stock-summary
Debt Equity

-0.27

stock-summary
Return on Equity

23.84%

stock-summary
Price to Book

7.07

Revenue and Profits:
Net Sales:
305 Million
(Quarterly Results - Jun 2025)
Net Profit:
31 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
2456.82%
0%
2456.82%
6 Months
3813.04%
0%
3813.04%
1 Year
1053.85%
0%
1053.85%
2 Years
1707.23%
0%
1707.23%
3 Years
924.12%
0%
924.12%
4 Years
1039.24%
0%
1039.24%
5 Years
1710.14%
0%
1710.14%

RaySearch Laboratories AB for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
12.20%
EBIT Growth (5y)
35.45%
EBIT to Interest (avg)
16.94
Debt to EBITDA (avg)
1.05
Net Debt to Equity (avg)
-0.46
Sales to Capital Employed (avg)
1.23
Tax Ratio
22.43%
Dividend Payout Ratio
50.54%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
18.78%
ROE (avg)
8.10%
Valuation key factors
Factor
Value
P/E Ratio
42
Industry P/E
Price to Book Value
9.49
EV to EBIT
30.03
EV to EBITDA
21.84
EV to Capital Employed
14.79
EV to Sales
6.17
PEG Ratio
1.51
Dividend Yield
0.99%
ROCE (Latest)
49.25%
ROE (Latest)
22.73%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2021stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -4.39% vs 33.15% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -49.84% vs 463.30% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "304.90",
          "val2": "318.90",
          "chgp": "-4.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "68.70",
          "val2": "80.00",
          "chgp": "-14.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "30.80",
          "val2": "61.40",
          "chgp": "-49.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "139.00%",
          "val2": "250.90%",
          "chgp": "-11.19%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 16.61% vs 21.17% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 149.39% vs 242.86% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,192.00",
          "val2": "1,022.20",
          "chgp": "16.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "546.40",
          "val2": "406.40",
          "chgp": "34.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "9.00",
          "val2": "9.70",
          "chgp": "-7.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "203.50",
          "val2": "81.60",
          "chgp": "149.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "207.20%",
          "val2": "117.60%",
          "chgp": "8.96%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
304.90
318.90
-4.39%
Operating Profit (PBDIT) excl Other Income
68.70
80.00
-14.12%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
30.80
61.40
-49.84%
Operating Profit Margin (Excl OI)
139.00%
250.90%
-11.19%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is -4.39% vs 33.15% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -49.84% vs 463.30% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
1,192.00
1,022.20
16.61%
Operating Profit (PBDIT) excl Other Income
546.40
406.40
34.45%
Interest
9.00
9.70
-7.22%
Exceptional Items
0.00
0.00
Consolidate Net Profit
203.50
81.60
149.39%
Operating Profit Margin (Excl OI)
207.20%
117.60%
8.96%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 16.61% vs 21.17% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 149.39% vs 242.86% in Dec 2023

stock-summaryCompany CV
About RaySearch Laboratories AB stock-summary
stock-summary
RaySearch Laboratories AB
Software Products
RaySearch Laboratories publ AB is a Sweden-based medical technology company that develops software for radiation therapy of cancer. It markets and sells its products mainly in the United States and in Europe through license agreements with medical technology companies and scientific institutions. As of December 31, 2011, 15 of the Company’s products were launched, including the software platform ORBIT (optimization of radiation therapy beams by iterative technique), which is available in its main products, and is a non-clinical system which functions as a research and development environment. Additionally, its solutions include software for optimizing Intensity Modulated Radiation Therapy (IMRT) plans for photons, adaptive technology for IMRT treatments and software for proton treatments. The Company’s commercial partners are Philips, Nucletron and IBA Dosimetry, among others. In April 2014, it established a German subsidiary, RaySearch Germany GmbH.
Company Coordinates stock-summary
Company Details
Sveavagen 44, Box 3297 , STOCKHOLM None : 103 65
Registrar Details